Coronavirus company news summary – Akston and LakePharma partner on second-generation Covid-19 vaccine – Emergex Vaccines partners with Oswaldo Cruz Foundation to study Covid-19 vaccine in Brazil

6 January 2021 (Last Updated January 6th, 2021 09:22)

6 January 2021 

Medical insulin developer Akston Biosciences is partnering with biologics company and LakePharma to manufacture second-generation Covid-19 vaccine. According to the terms of the agreement, LakePharma will produce commercial quantities of AKS-452, Akston’s adjuvated Covid-19 vaccine candidate, which is expected to enter Phase I/II studies later this month.

Arch Biopartners announced that the University of Calgary Cumming School of Medicine has joined its Phase II trial for investigating its lead drug LSALT peptide (Metablok) for treating hospitalised Covid-19 patients. The drug prevents acute damage to the lungs, kidneys, and other associated complications caused by inflammation associated with Covid-19.

Emergex Vaccines has entered into an agreement with Oswaldo Cruz Foundation‘s  Institute of Technology on Immunobiologicals (Bio-Manguinhos/Fiocruz) in Brazil to develop a Covid-19 vaccine. The partners will employ Emergex’s next-generation synthetic T-Cell vaccine technology. They will work together to progress a vaccine through clinical trials and into use by the Brazilian health service.

Stemirna Therapeutics has obtained approval to conduct human trials of its Covid-19 vaccine from China’s medical regulator. Stemirna’s new vaccine is being jointly developed with Tibet Rhodiola Pharma and is based on the messenger RNA (mRNA) technology, according to reporting by Reuters.